SXTP
60 Degrees·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SXTP
60 Degrees Pharmaceuticals, Inc.
A growth-oriented specialty pharmaceutical company developing new treatments for infectious diseases
1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036
--
60 Degrees Pharmaceuticals, Inc., a Delaware corporation, was founded on June 1, 2022. The company is a specialty pharmaceutical company with the goal of leveraging cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. The company has successfully won regulatory approval for Arakoda, a malaria preventive treatment that has been on the market since late 2019. Currently, 60P's pipeline of research and development covers vector-borne, fungal and viral diseases utilizing the company's three future products.
Company Financials
EPS
SXTP has released its 2025 Q1 earnings. EPS was reported at -1.56, versus the expected -1.32, missing expectations. The chart below visualizes how SXTP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SXTP has released its 2025 Q3 earnings report, with revenue of 528.56K, reflecting a YoY change of 256.87%, and net profit of -2.32M, showing a YoY change of -7.25%. The Sankey diagram below clearly presents SXTP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
